8-K: Tempest Therapeutics Unveils Strong Clinical Data, Strategic Milestones

Tempest Therapeutics highlights positive clinical data for its oncology pipeline, including promising CAR-T results and a pivotal Phase 3 path for its HCC therapy.

Summary

• Tempest Therapeutics provided an updated corporate presentation detailing its oncology pipeline and strategic milestones through Q4 2027.
• The company's pipeline includes Amezalpat (TPST-1120) for 1L HCC, TPST-2003 for rrMM with EMD, and TPST-1495 for FAP, alongside other partnered CAR-T programs.
• Amezalpat (TPST-1120) demonstrated a 6-month improvement in median Overall Survival (OS) over the control arm (21 months vs. 15 months) in a Phase 1b/2 HCC study, with a Hazard Ratio (HR) of 0.65.
• TPST-2003, a CD19/BCMA Dual CAR-T, showed an Objective Response Rate (ORR) of 86.7% (13/15 patients) in relapsed/refractory Multiple Myeloma (rrMM) patients with extramedullary disease (EMD) in a Phase 1/2a trial.
• TPST-2003 also achieved a 100% hematological ORR and 88.9% stringent complete response/complete response (sCR/CR) in 18 patients, with a 12-month Progression-Free Survival (PFS) rate of 75.3%.
• The company has secured FDA, EMA, and NMPA agreement on the proposed Phase 3 pivotal study design for Amezalpat.
• Clinical development for TPST-2003, TPST-2206, TPST-3003, and TPST-4003 in China is 100% funded and operationalized by strategic partner Novatim Immune Therapeutics.
• TPST-1495, a dual EP2/4 antagonist, is advancing to a Phase 2 study for Familial Adenomatous Polyposis (FAP), which will be funded by the National Cancer Institute (NCI).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, driven by strong clinical data for both Amezalpat and TPST-2003, significant regulatory progress, and strategic partnerships that de-risk development and conserve capital. The pending funding for Amezalpat's Phase 3 is a minor caveat.

Positives

• Amezalpat (TPST-1120) showed a statistically significant 6-month improvement in median Overall Survival (21 months vs. 15 months) and a Hazard Ratio of 0.65 in 1L HCC, with 50% of patients in the amezalpat arm still in survival follow-up.
• Amezalpat's efficacy was consistent across key subpopulations, including PD-L1 negative patients, and demonstrated a manageable safety profile similar to the standard of care.
• TPST-2003 achieved a high Objective Response Rate (ORR) of 86.7% in rrMM patients with extramedullary disease (EMD), a challenging patient population.
• TPST-2003 exhibited a favorable safety profile with low rates of Grade 3 Cytokine Release Syndrome (CRS) (5%) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) (10%), comparable to or better than approved BCMA CAR-T therapies like Abecma and Carvykti.
• TPST-2003 demonstrated superior median Progression-Free Survival (PFS) of 22.9 months in EMD patients compared to 7.9 months for Abecma and 13.8 months for Carvykti.
• Regulatory agreements for Amezalpat's pivotal Phase 3 study have been secured with the FDA, EMA, and NMPA, along with FDA Orphan Drug and Fast Track Designations.
• Significant portions of the pipeline, specifically the clinical development of TPST-2003, TPST-2206, TPST-3003, and TPST-4003 in China, are fully funded by a strategic partner, Novatim Immune Therapeutics, reducing internal capital deployment.
• The Phase 2 study for TPST-1495 in FAP is NCI-funded, further demonstrating capital discipline and external validation.

Negatives

• Amezalpat's Phase 3 timelines are subject to securing a partnership and/or separate funding, indicating a potential future capital need or reliance on external collaboration.
• The presentation includes cross-trial comparisons for TPST-2003, which are inherently limited and may suggest misleading similarities or differences in outcomes due to variations in study design and reporting.

Risks

• Actual results could differ materially from forward-looking statements due to various factors, including the progress, scope, or timing of product candidate development.
• The company's ability to protect its intellectual property rights may impact future performance.
• The company's anticipated operations, financial position, ability to raise capital to fund operations, revenues, costs, or expenses are subject to risks.
• There are inherent risks in conducting cross-trial comparisons, and results should be interpreted with caution as they are not head-to-head comparisons.
• No representation is made as to the safety or effectiveness of product candidates currently under clinical study and not yet approved for marketing by the U.S. Food and Drug Administration.
• Reliance on publicly-available third-party data that Tempest Therapeutics has not independently verified carries risks regarding completeness or accuracy due to differences in study design, eligibility criteria, and how results are recorded.

Future Outlook

The company anticipates accelerating the development of advanced therapies for cancer patients, driven by a diversified oncology pipeline and capital discipline through strategic partnerships. Key milestones include advancing Amezalpat to a pivotal Phase 3 study for HCC, submitting a China BLA for TPST-2003 in 2027, and progressing multiple CAR-T and antagonist programs through various clinical phases, with several programs fully funded by partners or the NCI.

Management Comments

• Matthew Angel, Chief Executive Officer, signed the 8-K filing on behalf of Tempest Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that Tempest Therapeutics is strategically positioning itself in highly competitive but lucrative oncology markets, particularly with its CAR-T and HCC programs. The dual-target CAR-T approach with TPST-2003 for rrMM with EMD addresses a significant unmet need, as EMD patients typically have inferior outcomes with existing therapies. The strong OS data for Amezalpat in 1L HCC, coupled with regulatory agreements, positions it as a potential challenger in a market currently dominated by a single standard of care (atezolizumab + bevacizumab). The company's strategy of leveraging partner funding for significant portions of its pipeline demonstrates a prudent approach to capital management in the high-cost drug development industry.

Comparison to Industry Standards

• TPST-2003's safety profile (Grade 3 CRS 5%, Grade 3 ICANS 10%) is comparable to or better than approved BCMA CAR-T therapies: Abecma (Grade 3 CRS 9.3%, Grade 3 ICANS 4%) and Carvykti (Grade 3 CRS 4%, Grade 3 ICANS 2%).
• TPST-2003 demonstrated a significantly superior median PFS of 22.9 months for EMD patients compared to 7.9 months for Abecma and 13.8 months for Carvykti, suggesting a potential best-in-class profile for this challenging patient population.
• TPST-2003's ORR of 100% and sCR/CR of 89.5% compares favorably to GC012F (Gracell/AZ), which reported an ORR of 93.1% and sCR/CR of 82.8% in rrMM, with TPST-2003 showing a 12-month PFS rate of 74.6%+ versus GC012F's median PFS of 38.0 months (though median PFS for TPST-2003 was not reached).
• Amezalpat's Hazard Ratio of 0.65 for Overall Survival in 1L HCC compares favorably to the control arm (atezolizumab + bevacizumab), which is a current standard of care, indicating a meaningful clinical benefit.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong clinical data, regulatory progress, and de-risked development through partnerships.
• Patients: Potential for new, effective treatment options for challenging cancers like HCC and rrMM with EMD, as well as FAP.
• Investment Professionals: Provides clear milestones and positive data for investment analysis and decision-making.
• Regulatory Authorities: Demonstrates progress towards regulatory approvals and adherence to guidelines.

Next Steps

• Initiate Phase 2b IIT (China) enrollment for TPST-2003 in Q1 2026.
• File IND (U.S.) for TPST-3003 and TPST-4003 in Q2 2026.
• Start Phase 2b (U.S. registrational) enrollment for TPST-2003 in Q3 2026.
• Complete enrollment for TPST-2003 Phase 2b (China registrational) in Q4 2026.
• Submit China BLA for TPST-2003 in Q3 2027.
• Secure partnership and/or separate funding for Amezalpat Phase 3 development.
• Begin Phase 2 study for TPST-1495 in FAP in 1H 2026, with data expected in 2027.

Key Dates

Recommendation

The filing presents compelling clinical data for key pipeline assets, Amezalpat and TPST-2003, demonstrating superior efficacy and/or safety profiles compared to existing or competing therapies. Regulatory agreements for Amezalpat's pivotal Phase 3, coupled with FDA Fast Track and Orphan Drug designations, significantly de-risk its path to market. Furthermore, substantial portions of the pipeline are partner-funded, indicating strong external validation and efficient capital deployment. While Amezalpat's Phase 3 funding is pending, the overall strength of the data and strategic execution suggest significant upside potential, making it a strong buy for long-term investors.

Keywords

Tempest Therapeutics, TPST, Oncology, CAR-T, Hepatocellular Carcinoma, Multiple Myeloma, Familial Adenomatous Polyposis, Amezalpat, TPST-1120, TPST-2003, TPST-1495, PPAR Antagonist, CD19/BCMA, EP2/4 Antagonist, Clinical Trials, Phase 3, FDA Fast Track, Orphan Drug Designation, Biotechnology, Drug Development